title: Evaluation of WO2012032067 and WO2012055846: two selective PI3Kδ inhibitors, which is GSK-2269557?
abstract: Two applications each claim crystalline forms, salts and compositions of a single selective PI3Kδ inhibitor. The subject of both applications are specific, previously disclosed, 6-aryl-4-(5-aminomethyloxazol-2-yl)indazole derivatives, respectively N-[5-[4-[5-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]oxazol-2-yl]-1H-indazol-6-yl]-2-methoxy-3-pyridyl]methanesulfonamide and 2-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-5-[(4-isopropylpiperazin-1-yl)methyl]oxazole.
authors: Norman Consulting, 18 Pink Lane, Burnham, Bucks, SL1 8JW, UK. peter.norman2@btinternet.com
authors: Peter
authors: P
authors: Norman
mesh_terms: D000818:Animals; D006801:Humans; D007880:Legislation, Drug; D015394:Molecular Structure; D010330:Patents as Topic; D058539:Phosphatidylinositol 3-Kinase / Q000737:chemistry / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011487:Protein Conformation; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship
chemical_list: D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D058539:Phosphatidylinositol 3-Kinase